Notably, a mutation in EPHA2 causes constitutive kinase activation in and contributes to the development of lung squamous cell carcinoma (SCC)1, while mutations in EPHB6 appear to have significant pro-metastatic effects in non-small cell lung cancer (NSCLC) cells2. Here, EPHA2 is linked to non-small cell lung carcinoma.